RECRUITING

Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

Description

The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.

Conditions

Primary Sclerosing CholangitisBiliary Atresia
Talk to us

Related Conditions:

Primary Sclerosing CholangitisBiliary Atresia

Study Overview

On this page

Study Details

Study overview

The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.

The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

Condition
Primary Sclerosing Cholangitis
Intervention / Treatment

-

Contacts and Locations

Sacramento

Sacramento Pediatric Gastroenterology, Sacramento, California, United States, 95841

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Persons who have primary sclerosing cholangitis, biliary atresia, a chronic intestinal disorder or who are undergoing upper or lower endoscopy.
  • * Persons who have primary sclerosing cholangitis or biliary atresia who are good candidates for vancomycin therapy.
  • * Patients that have taken antibiotics and/or immunomodulators within the last 3 months will be excluded as this will alter the original bacterial flora.
  • * Females who are pregnant may not participate.

Ages Eligible for Study

2 Weeks to 40 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Sacramento Pediatric Gastroenterology,

Yinka Davies, M.D., PRINCIPAL_INVESTIGATOR, Sacramento Pediatric Gastroenterology

Study Record Dates

2028-07